JamesC.YaoMDPhD

Oncology • Houston, TX

Physician

Join to view full profile

Are you Dr. Yao?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 113 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. James Yao, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
Baylor College of MedicineResidency, Internal Medicine, 1995 - 1998
Baylor College of MedicineClass of 1995

Certifications & Licensure

FL State Medical License 2021 - Present
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
WA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
TN State Medical License 2023 - 2025
TX State Medical License 1997 - 2025
AL State Medical License 2023 - 2024
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract Start of enrollment: 2003 Mar 01
Completed
Phase 2
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma Start of enrollment: 2004 Dec 01
Terminated
Phase 1, Phase 2
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma Start of enrollment: 2008 Jan 01
Completed
Phase 2
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) Start of enrollment: 2011 Aug 01
Completed
Phase 1
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Start of enrollment: 2012 Sep 06
Completed
Phase 3
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 Jun 18
Completed
Phase 2
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
Shadi Chamseddine, Betul Gok Yavuz, Yehia I Mohamed, Sunyoung S Lee, James C Yao
Journal of Immunotherapy and Precision Oncology. 2024-11-01
EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms.
Yoshiyuki Kiyasu, Xiangsheng Zuo, Yi Liu, James C Yao, Imad Shureiqi
Prostaglandins & Other Lipid Mediators. 2024-10-01
Classification of Gastric Neuroendocrine Tumors and Associations With Survival.
Yun Song, Eunise Chen, Yi-Ju Chiang, James C Yao, Daniel M Halperin
Journal of Surgical Oncology. 2024-09-10

Press Mentions

10 Things to Know About Neuroendocrine TumorsFebruary 23rd, 2024
HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary OfSeptember 8th, 2022
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-Ep Phase III Trial at ESMO Annual MeetingSeptember 25th, 2019
Join now to see all